Mortality Rates in Parkinson’s Disease and Their Association with Disease Duration

Pavankumar Kamat

Disclosures

September 01, 2021

Takeaway

  • Mortality rates in patients with Parkinson's disease (PD) in the UK increased slightly between 2006 and 2016, but they gradually increased year on year with advancing disease.

  • Overall, mortality rates decreased in patients with PD over 10 years, but this reduction was less pronounced than that in the general population.

Why this matters

  • Findings suggest that progression of PD is associated with increasing mortality, and reduction in mortality will require treatments to address the underlying disease progression, complications and associated comorbidities.

Study design

  • A study of 10,104 patients with a first diagnosis of PD who received ≥2 prescriptions of any antiparkinsonian drug actively registered within a general practice and 55,664 matched control participants from The Health Improvement Network (THIN; 2006-2016) database.

  • Funding: None.

Key results

  • After adjustment for confounders, the overall mortality rate was slightly increased in the PD vs control group (adjusted rate ratio, 1.14; 95% CI, 1.09-1.20; P<.001).

  • Adjusted mortality rates per 1000 person-years were lower in patients with PD vs control group in the year following diagnosis, but mortality rates gradually increased with each year from 43 (95% CI, 38-48) per 1000 person-years in the first year to 75 (95% CI, 64-85) per 1000 person-years at 5 years after diagnosis.

  • After adjustment for confounders, overall mortality rates declined more slowly over 10 years in patients with PD (2% per year or 1.2 per 1000 person-years) vs the control group (5% per year or 2.4 per 1000 person-years).

Limitations

  • The study cannot rule out the underdiagnosis of PD.

  • Misclassification of PD cases.

 

Okunoye O, Horsfall L, Marston L, Walters K, Schrag A. Mortality of People with Parkinson's Disease in a Large UK-Based Cohort Study: Time Trends and Relationship to Disease Duration. Mov Disord. 2021 Aug 05 [Epub ahead of print]. doi: 10.1002/mds.28727. PMID: 34351000.  View full text

This clinical summary originally appeared on Univadis, part of the Medscape Professional Network.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....